For anti-PLA2R/TSHD7A Indirect Immunofluorescent Antibody Assay (IFA) development and related research
Primary membranous nephropathy (PMN) is a kidney-specific, autoimmune glomerular disease that presents with increased protein in the urine associated with a pathognomonic pattern of injury in glomeruli. MN is a rare disease with significant HLA Class II genetic restriction and yet with two autoantigens described, it displays a remarkably consistent immunopathology based on deposition of autoantibodies in the subepithelial side of the glomerular basement membrane (GBM), a similar clinical presentation and response to therapy.
In 2009, PLA2R was defined as the predominant autoantigen in 72% of primary membranous nephropathy (MN) cases by western blotting studies using patient serum autoantibodies [1].
THSD7A is defined as the second autoantigen in MN using a similar methodological approach but only accounts for a small amount (up to 2%) of MN cases.
Creative Diagnostics now can provide PLA2R and THSD7A high expressed stable cell lines, which can be used in PLA2R/TSHD7A autoantibody IFA development. Anti-PLA2R/THSD7A IFA Kit is also available for research use.
Typical Data
Figure 1 | Indirect immunofluorescence using anti-PLA2R positive serum in PLA2R stable cell line (a) and control cell line (b)
Figure 2 | Slides in CD Cat# DIFA-02
PLA2R-Test: PLA2R-transfected cells
PLA2R-Blank: Control transfected cells
TSHD7A-Test: TSHD7A-transfected cells
TSHD7A-Blank: Control transfected cells
PC & NC: PLA2R-transfected cells
References
- Beck Jr, Laurence H., et al. "M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy." New England Journal of Medicine 361.1 (2009): 11-21.
- Fresquet, M., et al. "Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain." Journal of Autoimmunity 106 (2020): 102308.